Kids & teens (for parents) · Connecticut
Studies for children and teens in Connecticut
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
20 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company
- Location
- Stamford, CT + 11 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
H. Lundbeck A/S
- Location
- Stamford, CT + 8 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S
- Location
- New Haven, CT + 13 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A/S
- Location
- Stamford, CT + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Farmington, CT + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
argenx
- Location
- Hartford, CT + 10 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
- Location
- Hartford, CT + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
- Location
- Hartford, CT + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- New Haven, CT + 26 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Cromwell, CT + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Cromwell, CT + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Neurocrine Switzerland GmbH
- Location
- Hartford, CT + 10 other US sites
- Eligibility basics
- Ages 4 mo–3
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Stamford, CT + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
Mannkind Corporation
- Location
- New Haven, CT + 9 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company
- Location
- New Haven, CT + 39 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2/Phase 3
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Calcilytix Therapeutics, Inc., a BridgeBio company
- Location
- New Haven, CT + 3 other US sites
- Eligibility basics
- Ages 0 mo–17
- RecruitingPhase 1/Phase 2
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Noveome Biotherapeutics, formerly Stemnion
- Location
- New Haven, CT + 7 other US sites
- Eligibility basics
- Ages 0 mo–2 mo
- RecruitingHealthy volunteers
Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants
University of Alabama at Birmingham
- Location
- New Haven, CT + 1 other US site
- Eligibility basics
- Ages 1 mo–5 mo
- RecruitingHealthy volunteers
OSA-18 in Children With Mild Obstructive Sleep Apnea: Can it be a Helpful Decision Making Tool?
Connecticut Children's Medical Center
- Location
- Hartford, CT
- Eligibility basics
- Ages 3–12
- RecruitingHealthy volunteers
Effect of Force Magnitude on Canine Retraction and Gingival Crevicular Fluid Proteome
UConn Health
- Location
- Farmington, CT
- Eligibility basics
- Ages 11–16